

Prospective Genetic Screening Decreases the Incidence of Abacavir Hypersensitivity Reactions in the Western Australian HIV Cohort Study

A. Rauch,^{1,2} D. Nolan,¹ A. Martin,¹ E. McKinnon,¹ C. Almeida,¹ and Simon Mallal¹

¹Centre for Clinical Immunology and Biomedical Statistics, Perth, Australia; and ²Division of Infectious Diseases, University Hospital Berne, Switzerland

(See the editorial commentary by Phillips on pages 103–5)

Abacavir therapy is associated with significant drug hypersensitivity in ~8% of recipients, with retrospective studies indicating a strong genetic association with the *HLA-B*5701* allele. In this prospective study, involving 260 abacavir-naïve individuals (7.7% of whom were positive for *HLA-B*5701*), we confirm the usefulness of genetic risk stratification, with no cases of abacavir hypersensitivity among 148 *HLA-B*5701*-negative recipients.

Abacavir drug hypersensitivity represents an idiosyncratic, multisystem inflammatory reaction that occurs in 5%–8% of white patients initiating this commonly prescribed HIV drug [1, 2]. Clinical symptoms appear in >90% of cases within 6 weeks of commencing abacavir treatment [1] and include fever, rash, gastrointestinal symptoms, and lethargy or malaise. A history of definite abacavir hypersensitivity precludes any further use of abacavir, because rechallenge can evoke severe and potentially life-threatening reactions.

Clinical risk factors associated with abacavir hypersensitivity have been described, with relative protection associated with African racial origin, male sex, and more-advanced HIV disease stage in a meta-analysis of >8000 subjects in 34 clinical trials [2]. Higher CD8⁺ T cell count at the time of initiating abacavir treatment has also been associated with abacavir hypersensitivity [3]. However, genetic susceptibility conferred by the pres-

ence of a specific HLA allele—*HLA-B*5701*—appears to represent the dominant risk factor for abacavir hypersensitivity [4–8]. The frequency distribution of this genetic marker in different populations is likely to provide a rational basis for racially defined differences in susceptibility [7, 9], whereas the critical role of *HLA-B*5701* in generating and directing CD8⁺ T cell-dependent, HLA-restricted immune responses suggests a key role for this genetic variant in the pathogenesis of an abacavir-specific immune response [6, 8].

Following the recognition of a strong predictive association between *HLA-B*5701* carriage and abacavir hypersensitivity in our study population in 2001, a prospective testing strategy was commenced on the basis that *HLA-B*5701* testing could sharply discriminate individual risk of developing abacavir hypersensitivity into low-risk (<1%) and high-risk (>70%) groups [4]. Abacavir prescription was therefore avoided in *HLA-B*5701*-positive patients in the Western Australian HIV cohort from 2002 onwards. Here, we describe a single-center cohort study involving all abacavir-naïve individuals starting or changing antiretroviral therapy (ART) during a study period from January 2002 through July 2005 (a total of 260 subjects). The study included 121 initial ART prescriptions and 214 nucleoside reverse-transcriptase inhibitor (NRTI) treatment changes among 178 abacavir-naïve patients (39 of whom were also considered in the analysis of ART-naïve patients). As a component of routine clinical care, high-resolution HLA class I and class II typing (*HLA-A*, *HLA-B*, *HLA-C*, *HLA-DR*, and *HLA-DQ*) was undertaken for all subjects by direct DNA sequencing, as described elsewhere [4, 6]. Diagnostic classification of abacavir hypersensitivity reactions in this study population was performed using standardized clinical criteria [1, 2, 4, 6]. Therefore, a diagnosis of abacavir hypersensitivity required the presence of at least 2 symptoms of fever, rash, nausea, vomiting, headache, respiratory and gastrointestinal symptoms, lethargy, myalgia, or arthralgia, occurring <6 weeks after initial abacavir exposure. Patients stopping abacavir therapy within 6 weeks after initiation because of symptoms that did not meet the diagnostic criteria for abacavir hypersensitivity were also assessed. Adjunctive epicutaneous patch testing [8] was performed in all suspected cases of abacavir hypersensitivity and in unclear cases for which patients provided consent. All cases in which abacavir treatment was discontinued within 6 weeks after commencing therapy with the drug were examined, both in the prospective study period (January 2002 through July 2005) and in the period before the introduction of pharmacogenetic screening (January 1998 through December 2001).

Received 3 February 2006; accepted 13 March 2006; electronically published 26 May 2006.

Reprints or correspondence: Prof. Simon Mallal, Centre for Clinical Immunology and Biomedical Statistics, 2nd Fl., North Block, Royal Perth Hospital, Wellington St., Perth 6000, Western Australia (S.Mallal@murdoch.edu.au).

Clinical Infectious Diseases 2006;43:99–102

© 2006 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2006/4301-0015\$15.00

As shown in table 1, patients starting abacavir therapy did not differ significantly from those starting therapy with alternative antiretroviral drugs with respect to sex, age, ethnicity, and route of HIV infection. Patients not commencing abacavir therapy had more-advanced HIV disease (i.e., significantly higher HIV loads, lower CD4⁺ cell counts, and more-frequent AIDS-defining events), compared with patients starting abacavir therapy, reflecting the limited use of abacavir for patients with more-advanced HIV disease during the 2002–2005 study period, when abacavir was frequently incorporated into triple-NRTI regimens (i.e., zidovudine-lamivudine-abacavir therapy). Overall patterns of NRTI drug prescription are presented in table 2.

Among 121 treatment-naïve patients initiating first-line HIV therapy, 112 (92.6%) were found to be negative for the *HLA-B*5701* allele, of whom 42 (37.5%) started abacavir therapy (tables 1 and 2). In 2 of these cases, abacavir was discontinued within 6 weeks after initiation because of symptoms that were

not consistent with drug hypersensitivity (diarrhea in 1 patient and headache probably related to concurrent zidovudine treatment in 1 patient). Of the 9 ART-naïve, *HLA-B*5701*-positive patients identified by genetic screening, 1 patient started abacavir treatment before the review of HLA results. This 48-year-old white man subsequently developed a typical abacavir hypersensitivity reaction, characterized by the development of a widespread maculopapular rash, fever, and constitutional symptoms 6 days after commencing abacavir therapy. Treatment was discontinued 2 days later, with resolution of symptoms within 24 h after discontinuation of therapy. A positive epicutaneous patch test result was subsequently recorded with vesicular, erythematous skin changes following application of both 1% and 10% abacavir concentrations in a petrolatum vehicle.

During this study period, 178 ART-experienced but abacavir-naïve patients switched NRTI therapy. From this group, 164 (92.1%) were identified as *HLA-B*5701*-negative patients. Abacavir was prescribed for 106 (64.6%) of these individuals; 90

Table 1. Characteristics of abacavir-naïve, HIV-infected patients commencing or changing antiretroviral therapy.

Patient characteristics	Treatment-naïve group		<i>P</i>	Treatment-experienced group ^a		<i>P</i>
	Started abacavir therapy (<i>n</i> = 43)	Did not start abacavir therapy (<i>n</i> = 78)		Started abacavir therapy ^b (<i>n</i> = 92)	Did not start abacavir therapy (<i>n</i> = 86)	
Sex						
Male	36 (83)	57 (73)		72 (78)	70 (81)	
Female	7 (16)	21 (27)	.3	20 (22)	16 (19)	.7
Age, median years (IQR)	43 (36–49)	39 (30–46)	.1	41 (35–51)	41 (33–50)	.4
Ethnicity						
White	32 (74)	57 (73)		70 (76)	66 (77)	
Aboriginal	3 (7)	7 (9)		8 (9)	8 (9)	
African	4 (9)	4 (5)		7 (8)	3 (3)	
Asian	4 (9)	10 (13)	.8	7 (8)	9 (10)	.6
Route of HIV infection						
MSM	19 (44)	31 (40)		51 (55)	41 (47)	
Other	24 (56)	47 (60)	.7	41 (44)	45 (52)	.3
Immunological status						
CD4 ⁺ cell count, median cells/μL (IQR)	352 (240–464)	285 (84–420)	.03	479 (253–726)	287 (96–442)	<.001
CD8 ⁺ cell count, median cells/μL (IQR)	948 (633–1403)	762 (470–1160)	.06	884 (644–1255)	837 (539–1159)	.2
HIV RNA load ^c						
<50 copies/mL	NA	NA		50 (54)	24 (28)	
50–10 ⁵ copies/mL	30 (73)	23 (32)		33 (36)	30 (35)	
>10 ⁵ copies/mL	11 (27)	49 (68)	<.001	9 (10)	32 (37)	<.001
CDC stage						
Prior CDC stage C event	2 (5)	13 (17)		14 (15)	25 (29)	
No prior CDC stage C event	41 (95)	65 (83)	.08	78 (85)	61 (70)	.03
<i>HLA-B*5701</i> status						
Positive	1 (2)	8 (10)		2 (2)	12 (14)	
Negative	42 (97)	70 (89)	.15	90 (98) ^b	74 (86)	.004

NOTE. Data are no. (%) of patients, unless otherwise indicated. Data are for time of commencing antiretroviral therapy or at time of first treatment change. Characteristics at the time of commencing or changing antiretroviral therapy were compared by use of χ^2 and Mann-Whitney *U* tests. CDC, Centers for Disease Control and Prevention; IQR, interquartile range; MSM, men who have sex with men; NA, not available.

^a Includes 39 patients considered in the treatment-naïve analysis who did not start abacavir therapy as part of the first course of antiretroviral therapy.

^b An additional 16 *HLA-B*5701*-negative patients started abacavir subsequently (i.e., for their second or third change in antiretroviral therapy).

^c Information on HIV load was not available at this time point for 8 (6%) of 121 abacavir-naïve patients.

Table 2. Choice of nucleoside reverse-transcriptase inhibitor (NRTI) therapy in abacavir-naïve patients.

NRTI	No. (%) of patients			
	Treatment-naïve group		Treatment-experienced group ^a	
	HLA-B*5701-negative patients (n = 112)	HLA-B*5701-positive patients (n = 9)	HLA-B*5701-negative patients (n = 164)	HLA-B*5701-positive patients (n = 14)
Abacavir ^b	42 (37)	1 (11)	90 (55)	2 (14)
Zidovudine	70 (62)	6 (66)	45 (27)	5 (36)
Lamivudine	109 (97)	8 (89)	63 (38)	5 (36)
Stavudine	3 (3)	1 (11)	5 (3)	1 (7)
Didanosine	2 (2)	1 (11)	7 (4)	2 (14)
Tenofovir	14 (12)	2 (22)	34 (20)	6 (43)

^a First treatment change.

^b Abacavir-lamivudine-zidovudine (Trizivir; GlaxoSmithKline) accounts for 16 (37%) of 43 abacavir prescriptions in treatment-naïve patients and 38 (41%) of 92 abacavir prescriptions in patients receiving second-line HIV therapy. Overall, 48 (89%) of 54 of abacavir-lamivudine-zidovudine prescriptions were for patients with a CD4⁺ cell count >200 cells/ μ L, and 51 (94%) of 54 prescriptions were for patients with an HIV RNA level <10⁵ copies/mL.

patients started abacavir therapy at the time of their first treatment change (tables 1 and 2), and 16 patients started abacavir therapy subsequently (at the second or third change in ART). In 4 cases, abacavir was discontinued within 6 weeks. One patient developed nonspecific symptoms of headache and cold sweats that were not responsive to abacavir withdrawal within 1 week after withdrawal of therapy, and 2 patients developed symptoms of nausea and vomiting attributed to nevirapine (including rash in 1 patient) that were associated with negative epicutaneous patch test results. One patient suffered from HIV-associated dermatosis that was present before starting abacavir therapy. Of the 14 ART-experienced, HLA-B*5701-positive patients who were screened, 2 started abacavir therapy. In 1 case, HLA test results were not reviewed before drug prescription, and 1 patient made an informed choice to initiate abacavir therapy because HLA typing demonstrated the absence of HLA-B57-associated ancestral haplotype markers in central and class II major histocompatibility complex regions (i.e., C4A6 and HLA-DR7/HLA-DQ3). This patient also had limited treatment options because of previous treatment complications (e.g., severe lipodystrophy). Both of these white patients experienced abacavir hypersensitivity reactions, confirmed with epicutaneous patch test results that were strongly positive to 1% and 10% abacavir concentrations.

Overall, the incidence of abacavir hypersensitivity in this prospectively screened population was 3 (2.0%) of 151 patients, with no cases diagnosed among the 148 HLA-B*5701-negative patients who received abacavir treatment. Therefore, the incidence of abacavir hypersensitivity decreased significantly ($P = .01$, by Fisher's exact test), compared with the 8% prevalence of abacavir hypersensitivity before genetic screening (figure 1), a result that was consistent with published data in predominantly white patient cohorts [2, 3, 10]. The proportion of patients stopping abacavir therapy because of symptoms that did

not meet diagnostic criteria for drug hypersensitivity during the first 6 weeks of therapy also decreased, from 8.5% before genetic screening to 4.0% after introduction of screening ($P = .1$, by Fisher's exact test) (figure 1). These results, although reinforcing the positive predictive value of HLA-B*5701 testing for these patients, also demonstrate that failure to review HLA results before abacavir prescription can have significant adverse




Figure 1. Proportion of patients stopping abacavir therapy in the first 6 weeks of treatment before and after introduction of prospective genetic screening. The numbers below the time periods indicate the number of abacavir-naïve individuals starting abacavir therapy. The upper line (●) indicates the proportion of patients who stopped abacavir therapy because of any symptoms in the first 6 weeks of therapy; the number of patients indicated below the circle indicates the total number of patients with "minor" symptoms (abacavir hypersensitivity not excluded) plus the number of patients with definitive abacavir hypersensitivity reactions. The bottom line (◆) indicates the proportion of patients with definitive abacavir hypersensitivity reactions; the number of patients in the respective time period is indicated below the diamonds.

consequences. Therefore, a system has now been developed whereby *HLA-B*5701*-positive results are routinely noted in the allergy field of the pharmacy system database, ensuring that abacavir is not dispensed to *HLA-B*5701*-positive patients without prior explicit knowledge and consent of the treating clinician.

The prevalence of *HLA-B*5701* carriage in this population was 20 (7.7%) of 260 patients, all of whom were identified as white, which is consistent with expected results from population-based HLA data. It is also notable that high-resolution HLA typing methods used in this study were able to discriminate the *HLA-B*5701* allele from closely related alleles, such as *HLA-B*5702* (in 2 cases), *HLA-B*5703* (in 1 case), and *HLA-B*5801/5802* (in 9 cases). Subjects with these HLA alleles were prescribed abacavir (including 2 subjects with *HLA-B*5702*, 1 subject with *HLA-B*5703*, and 3 subjects with *HLA-B*5801*) without incident, indicating that susceptibility is mapped specifically to the *HLA-B*5701* allele and its related major histocompatibility complex haplotype.

We, therefore, conclude that prospective genetic screening with avoidance of abacavir prescription in patients carrying the susceptibility marker *HLA-B*5701* has had a dramatic impact on the incidence of abacavir hypersensitivity in the Western Australian HIV Cohort. We acknowledge that assessing the broader clinical implications of this approach to abacavir prescribing in racially diverse HIV-infected populations requires further study, which may be conducted in light of the expected frequency distribution of *HLA-B*5701* and its associated major histocompatibility complex haplotype in these population groups [9]. However, given the otherwise favorable safety profile of abacavir once drug hypersensitivity is excluded [11], this pharmacogenomic approach to risk stratification would appear to pave the way for more confident abacavir prescription.

Acknowledgments

We are indebted to Prof. Martyn French, Prof. Frank Christiansen, Dr. Olga Martinez, Dr. Mina John, Dr. Chris Heath, and Dr. Ronan Murray,

for their clinical support, and to Dr. Elizabeth Phillips and Sunnybrook Hospital Pharmacy Manufacturing (Toronto, Canada), for providing the patch testing protocol and reagents.

Financial support. Australian National Health and Medical Research Council (project grant 237408). A.R. received a Fellowship for Prospective Researchers from the Swiss National Science Foundation.

Potential conflicts of interest. S.M. has served as a consultant to and received research support from GlaxoSmithKline. S.M. and D.N. are members of the speakers' bureau for GlaxoSmithKline. All other authors: no conflicts.

References

1. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. *Clin Ther* **2001**; 23:1603–14.
2. Cutrell AG, Hernandez JE, Fleming JW, et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. *Ann Pharmacother* **2004**; 38:2171–2.
3. Easterbrook PJ, Waters A, Murad S, et al. Epidemiological risk factors for hypersensitivity reactions to abacavir. *HIV Med* **2003**; 4:321–4.
4. Mallal S, Nolan D, Witt C, et al. Association between presence of *HLA-B*5701*, *HLA-DR7*, and *HLA-DQ3* and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. *Lancet* **2002**; 359:727–32.
5. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. *Lancet* **2002**; 359:1121–2.
6. Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by *HLA-B*5701* and a haplotypic Hsp70-Hom variant. *Proc Natl Acad Sci U S A* **2004**; 101:4180–5.
7. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. CNA30032 Study Team. *Pharmacogenomics* **2004**; 5:203–11.
8. Phillips EJ, Wong GA, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. *AIDS* **2005**; 19:979–81.
9. Nolan D, Gaudieri S, Mallal S. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? *J HIV Ther* **2003**; 8:36–41.
10. Peyriere H, Guillemin V, Lotthe A, et al. Reasons for early abacavir discontinuation in HIV-infected patients. *Ann Pharmacother* **2003**; 37:1392–7.
11. Dando TM, Scott LJ. Abacavir plus lamivudine: a review of their combined use in the management of HIV infection. *Drugs* **2005**; 65:285–302.